Evidence map›Paper›PMID 33215845›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2021

Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia.

Kamen A Tsvetanov, Stefano Gazzina, P Simon Jones, John van Swieten, Barbara Borroni, Raquel Sanchez-Valle, Fermin Moreno, Robert Laforce, Caroline Graff, Matthis Synofzik and 20 more

Open access · hybridAbstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 67 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Sex differences in the executive and behavioral reserve of autosomal dominant frontotemporal dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Locus Coeruleus Integrity Is Linked to Response Inhibition Deficits in Parkinson's Disease and Progressive Supranuclear Palsy.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2023
    Article
  15. Review
  16. Frontotemporal lobar degeneration.Nature reviews. Disease primers · 2023
    Review
  17. Article
  18. Article
  19. Temporal dynamics predict symptom onset and cognitive decline in familial frontotemporal dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 20 institutions in 11 countries.

Kamen A TsvetanovDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Stefano GazzinaDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
P Simon JonesDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
John van SwietenDepartment of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands.
Barbara BorroniCentre for Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Raquel Sanchez-ValleAlzheimer's disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Institut d'Investigacións Biomèdiques August Pi I Sunyer, University of Barcelona, Barcelona, Spain.
Fermin MorenoCognitive Disorders Unit, Department of Neurology, Hospital Universitario Donostia, San Sebastian, Gipuzkoa, Spain.
Robert LaforceClinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques, CHU de Québec, and Faculté de Médecine, Université Laval, Québec, Canada.
Caroline GraffDepartment NVS, Center for Alzheimer Research, Division of Neurogenetics, Karolinska Institutet, Stockholm, Sweden.
Matthis SynofzikDepartment of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research & Center of Neurology, University of Tübingen, Germany.
Daniela GalimbertiCentro Dino Ferrari, University of Milan, Milan, Italy.
Mario MasellisLC Campbell Cognitive Neurology Research Unit, Sunnybrook Research Institute, Department of Medicine (Neurology), University of Toronto, Toronto, Ontario, Canada.
Maria Carmela TartagliaTanz Centre for Research in Neurodegenerative Disease, Toronto Western Hospital, Toronto, Ontario, Canada.
Elizabeth FingerDepartment of Clinical Neurological Sciences, University of Western Ontario, London, Ontario, Canada.
Rik VandenbergheLaboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium.
Alexandre de MendonçaLaboratory of Neurosciences, Faculty of Medicine, Institute of Molecular Medicine, University of Lisbon, Lisbon, Portugal.
Fabrizio TagliaviniFondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta, Milan, Italy.
Isabel SantanaNeurology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
Simon DucharmeDepartment of Psychiatry, McGill University Health Centre, McGill University, Montreal, Canada.
Chris ButlerNuffield Department of Clinical Neurosciences, Medical Sciences Division, University of Oxford, Oxford, UK.
Alexander GerhardDivision of Neuroscience and Experimental Psychology, Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK.
Adrian DanekNeurologische Klinik und Poliklinik, German Center for Neurodegenerative Diseases (DZNE), Ludwig-Maximilians-Universität, Munich, Munich, Germany.
Johannes LevinGerman Center for Neurodegenerative Diseases, Munich Cluster for Systems Neurology (Synergy), Munich, Germany.
Markus OttoDepartment of Neurology, University Hospital Ulm, Ulm, Germany.
Giovanni FrisoniIstituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
Roberta GhidoniMolecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
Sandro SorbiDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.
Jonathan D RohrerDementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.
James B RoweDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Genetic FTD Initiative, GENFIDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Erasmus MC · NLGerman Center for Neurodegenerative Diseases · DEUniversity of Cambridge · GBBiogipuzkoa Health Research Institute · ESCentro San Giovanni di Dio Fatebenefratelli · ITConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESFondazione IRCCS Istituto Neurologico Carlo Besta · ITHospitais da Universidade de Coimbra · PTIstituti di Ricovero e Cura a Carattere Scientifico · ITKarolinska Institutet · SEKU Leuven · BEMcGill University Health Centre · CAMRC Cognition and Brain Sciences Unit · GBToronto Western Hospital · CAUK Dementia Research Institute · GBUniversité Laval · CAUniversity Hospital Ulm · DEUniversity of Brescia · ITUniversity of Florence · ITUniversity of Lisbon · PT

Funding

Medical Research Council MC_U105597119Medical Research Council MC_UU_00005/12Medical Research Council MC_UU_00024/1Medical Research Council MR/J009482/1Medical Research Council MR/M008525/1Medical Research Council MR/M023664/1Medical Research Council MR/T046015/1Wellcome Trust 103838
6 · The paper itself

Abstract

introductionThe presymptomatic phase of neurodegenerative disease can last many years, with sustained cognitive function despite progressive atrophy. We investigate this phenomenon in familial frontotemporal dementia (FTD).

methodsWe studied 121 presymptomatic FTD mutation carriers and 134 family members without mutations, using multivariate data-driven approach to link cognitive performance with both structural and functional magnetic resonance imaging. Atrophy and brain network connectivity were compared between groups, in relation to the time from expected symptom onset.

resultsThere were group differences in brain structure and function, in the absence of differences in cognitive performance. Specifically, we identified behaviorally relevant structural and functional network differences. Structure-function relationships were similar in both groups, but coupling between functional connectivity and cognition was stronger for carriers than for non-carriers, and increased with proximity to the expected onset of disease. DISCUSSION: Our findings suggest that the maintenance of functional network connectivity enables carriers to maintain cognitive performance.

Indexed as

Prodromal SymptomsAtrophyBrainC9orf72 ProteinCognitionFrontotemporal DementiaHumansInternationalityMagnetic Resonance ImagingMiddle AgedMutationtau ProteinsC9orf72 ProteinMAPT protein, humantau Proteinsfrontotemporal dementia (FTD)functional magnetic resonance imaging (fMRI)network connectivitypresymptomatic

Identifiers

PMID33215845
PMCPMC7611220
OpenAlexW3102291668

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.